BMX-002（Biomunex Pharmaceuticals）

N/A

Report date: 2024/11/13 13:46:41

Base Information

Drug NameBMX-002（Biomunex Pharmaceuticals）
Drug Alias NameBMX-002
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulantsAnti-Epidermal growth factor receptor erbB1 +[4] 
TargetsEpidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBiomunex Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesBiomunex Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A